Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|ER+ Breast Cancer|Advanced Breast Cancer
Interventions: DRUG: Ipatasertib 300mg|DRUG: Fulvestrant 500g|DRUG: Palbociclib 75mg-125mg|DRUG: CDK4/6 Inhibitor
Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Pfizer|Hoffmann-La Roche